Emerging drugs for the treatment of acne

  title={Emerging drugs for the treatment of acne},
  author={Imran Aslam and Alan B. Fleischer and Steve Feldman},
  journal={Expert Opinion on Emerging Drugs},
  pages={101 - 91}
Introduction: Acne is the most common skin condition in the US. The mainstay of acne therapy includes: topical retinoids, topical antibiotics, benzoyl peroxide (BP), and oral isotretinoin for severe cases. Although these treatment options are highly effective they do have certain drawbacks. Current acne treatment regimens often require patients to use multiple medications, some of which may have irritating side effects. Furthermore, Propionibacterium acnes resistance to antibiotics has become… 

Evaluating FMX-101 as a promising therapeutic for the treatment of acne

The proven efficacy and safety profile of FMX-101, together with the low systemic absorption, high skin tolerability and cosmetically acceptable foam formulations render this novel therapy an important addition to the acne treatment armamentarium.

Emerging Therapies for Acne Vulgaris

Therapies for acne are constantly evolving and current gold-standard acne therapy may be supplemented with novel treatment modalities in the near future.

Minocycline Topical Foam: A New Drug for the Treatment of Acne

The foam has a good safety profile, with headache, mild erythema, hyperpigmentation, and mild dryness among the most common adverse effects and may help restore this important therapeutic approach for treating acne vulgaris.

What's new in acne and rosacea?

  • J. Keri
  • Medicine
    Seminars in cutaneous medicine and surgery
  • 2016
This review will discuss the most recent therapeutic options for patients with acne and rosacea, and the new topical agents - brimonidine gel and ivermectin cream - will be reviewed, with a discussion on possible rebound phenomenon from Brimonidine.

The immunomodulatory potential of phage therapy to treat acne: a review on bacterial lysis and immunomodulation

Phage therapy to treat acne can be a suitable therapeutic alternative to C. acnes control, which in turn can aid to restore the skin’s balance of microbiota.

Antibiotic resistance to Propionobacterium acnes: worldwide scenario, diagnosis and management

Genomic evaluation using 16S ribosomal RNA gene sequencing can be useful in diagnosing mutations and mapping phylotypes of Propionobacterium acnes, and the use of oral retinoids and non-antibiotics like zinc can prevent resistance and help reduce the dependence on antibiotics.

Clinical Pharmacokinetics, Safety and Exploratory Efficacy Study of a Topical Bactericidal VB-1953: Analysis of Single and Multiple Doses in a Phase I Trial in Acne Vulgaris Subjects

VB-1953 topical gel appears to be safe for use in adults with facial acne vulgaris and may offer new advances as a topical antibiotic agent for the disease.

Efficacy and Safety of VB-1953 Topical Gel in Non-Responder Acne Patients with Clindamycin-Resistant Cutibacterium acnes

Results indicate that VB-1953 topical gel can be a safe and effective therapy for moderate to severe acne with underlying resistant C. acnes in subjects who had not responded to previous antibiotic treatments.

Development of an effective formulation for an acne treatment cream withOcimum basilicumusing invasomes

  • H. Han
  • Biology
    Journal of Cosmetic Medicine
  • 2018
This study proposes that, along with the formulation of a micro-emulsion, the use of invasomes will offer an effective advanced drug delivery system that promises improved efficacy and stability in treating acne with O. basilicum.



Novel pharmacological approaches for the treatment of acne vulgaris

The authors believe that there will likely be a decline in the use of antibiotics for controlling P. acnes colonization and targeting the inflammation cascade, and Retinoic acid metabolism-blocking agents and IL-1α inhibitors have the potential to become legitimate alternative options to retinoid therapy in the management of infundibular dyskeratosis.

Novel pharmacological approaches for the treatment of acne vulgaris.

The authors discuss and evaluate the pathogenic pathways related to the mechanisms of action of novel molecules, which are currently under investigation for the treatment of acne vulgaris.

Clindamycin phosphate/tretinoin gel formulation in the treatment of acne vulgaris.

The once daily use of CTG, its rapid and dual effect and good tolerability have a positive impact on the duration of disease, patients' compliance and overall costs of therapy.

Subantimicrobial dose doxycycline for acne and rosacea.

Subantimicrobial dose doxycycline (Periostat 20 mg) has clinical utility in periodontitis and has been investigated in a double-blind, placebo-controlled, and open label study in the treatment of rosacea.

Safety and side effects of the acne drug, oral isotretinoin.

The most common adverse events, observed during treatment, are mucocutaneous and ophthalmological and laboratory abnormalities and effects in the nervous, musculoskeletal, gastrointestinal, pulmonary and other systems have been described.

Subantimicrobial-dose doxycycline in the treatment of moderate facial acne.

Subantimicrobial-dose doxycycline administered twice daily for 3 months in patients with moderate inflammatory acne results in significant reduction in the number of total inflammatory lesions.

A Novel Gel Formulation of 0.25% Tretinoin and 1.2% Clindamycin Phosphate: Efficacy in Acne Vulgaris Patients Aged 12 to 18 Years

This novel CLIN/RA gel for treating acne is tolerable and safe and offers clinicians and teen aged patients a new and efficacious intervention for acne vulgaris.

Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment.

Results show that dapsone gel 5% is safe and effective for long-term treatment of acne vulgaris and has a rapid onset of action.

Topical ALA-photodynamic therapy for the treatment of acne vulgaris.

There was clinical and statistically significant clearance of inflammatory acne by aminolevulinic acid plus red light, for at least 20 wk after multiple treatments and 10 wK after a single treatment, in an open-label prospective human study of acne vulgaris.

Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid versus methyl aminolevulinate.